{
    "nctId": "NCT03407768",
    "briefTitle": "Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer",
    "officialTitle": "Role of Individualized Intervention(s) on Quality of Life and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Early-Stage Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Premenopausal Breast Cancer, Hormone Receptor Positive Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 41,
    "primaryOutcomeMeasure": "Functional Assessment of Cancer Therapy - Breast Symptom Index (FACT-B)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n\u2022 Premenopausal women with histologically-proven, completely resected, hormone receptor-positive (defined as ER\u226510% and/or PgR\u226510%) stage 1, 2, and 3 invasive breast cancer who are treated with combination of anti-estrogen therapy (LHRH agonist and an aromatase inhibitor or tamoxifen)\n\nExclusion Criteria:\n\n* Post-menopausal women\n* Women who are on single agent endocrine therapy",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}